Your session is about to expire
← Back to Search
NMDA Receptor Antagonist
Ketamine for Cardiac Arrest (KetCat Trial)
N/A
Recruiting
Research Sponsored by Fraser Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 6 months.
Awards & highlights
Summary
This trial is testing whether ketamine, a common sedative, can help improve brain function in people who have had a cardiac arrest. The goal is to see if ketamine can reduce the damage caused by lack of oxygen to the brain during cardiac arrest. Ketamine has been studied for its potential to protect the brain and improve outcomes after cardiac arrest.
Eligible Conditions
- Neurologic Symptoms
- Cardiac Arrest
- Ketamine
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 6 months.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 6 months.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Feasibility Data
Side effects data
From 2020 Phase 4 trial • 75 Patients • NCT031565041%
Lightheadedness with low blood pressure
1%
Pump Malfunction
1%
PTSD
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ketamine
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Ketamine ArmExperimental Treatment1 Intervention
Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment
Group II: Control ArmActive Control1 Intervention
Patients randomized to the control arm will not receive ketamine as part of their sedation medications during their cardiac arrest treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine Hydrochloride
2018
Completed Phase 4
~1890
Find a Location
Who is running the clinical trial?
Fraser HealthLead Sponsor
46 Previous Clinical Trials
707,566 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your heart stopped for more than 30 minutes without restarting.You have a known allergy or sensitivity to ketamine.Any other kind of sudden heart stopping.You are currently using a machine called Extracorporeal Membrane Oxygenation (ECMO).You live in a long-term care facility.You have had any previous or existing neurological problems.You are in prison.If you have a specific kind of heart rhythm problem called "shockable rhythm" and are being treated at Royal Columbian Hospital for a cardiac arrest, you can participate in the study.
Research Study Groups:
This trial has the following groups:- Group 1: Ketamine Arm
- Group 2: Control Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger